Raed Alroughani

List of Publications by Year
in descending order

120 papers	3,784 citations	172457 29 h-index	149698 56 g-index
127 all docs	127 docs citations	127 times ranked	3548 citing authors

#	Article	IF	Citations
1	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
2	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
3	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 2021, 97, e1870-e1885.	1.1	168
4	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
5	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
6	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	7.6	140
7	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.1	138
8	Pediatric multiple sclerosis: a review. BMC Neurology, 2018, 18, 27.	1.8	137
9	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
10	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS ONE, 2015, 10, e0122686.	2.5	122
11	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
12	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
13	Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology, 2018, 90, e840-e846.	1.1	86
14	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	1.9	76
15	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	3.0	73
16	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
17	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
18	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54

#	Article	IF	Citations
19	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
20	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
21	Migraine misdiagnosis as a sinusitis, a delay that can last for many years. Journal of Headache and Pain, 2013, 14, 97.	6.0	44
22	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
23	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
24	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
25	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
26	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
27	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
28	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	1.0	34
29	Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?. PLoS ONE, 2016, 11, e0165846.	2.5	31
30	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Multiple Sclerosis International, 2016, 2016, 1-8.	0.8	30
31	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
32	Use of traditional medicine for primary headache disorders in Kuwait. Journal of Headache and Pain, 2018, 19, 118.	6.0	29
33	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
34	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	2.5	26
35	Functional clinical outcomes in multiple sclerosis: Current status and future prospects. Multiple Sclerosis and Related Disorders, 2015, 4, 192-201.	2.0	26
36	Risk of relapses during pregnancy among multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2019, 34, 9-13.	2.0	25

#	Article	IF	Citations
37	Neuralgic amyotrophy associated with COVID-19 infection: a case report and review of the literature. Neurological Sciences, 2021, 42, 2161-2165.	1.9	25
38	JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. Journal of the Neurological Sciences, 2016, 360, 61-65.	0.6	24
39	Retinal nerve fiber layer thickness and neurologic disability in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2015, 359, 305-308.	0.6	23
40	The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. Pediatric Neurology, 2017, 70, 56-60.	2.1	22
41	Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. BMC Neurology, 2017, 17, 150.	1.8	22
42	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
43	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
44	An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. Neurology and Therapy, 2019, 8, 13-23.	3.2	22
45	Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study. Journal of Headache and Pain, 2021, 22, 97.	6.0	22
46	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
47	Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis. Multiple Sclerosis and Related Disorders, 2018, 21, 56-62.	2.0	20
48	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	9.0	20
49	Effects of prolonged fasting on fatigue and quality of life in patients with multiple sclerosis. Neurological Sciences, 2016, 37, 929-933.	1.9	19
50	Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence. Neurology and Therapy, 2017, 6, 189-196.	3.2	19
51	Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries. Multiple Sclerosis International, 2013, 2013, 1-6.	0.8	18
52	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
53	Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region. Neurology and Therapy, 2020, 9, 265-280.	3.2	18
54	Month of birth and risk of multiple sclerosis in Kuwait: A population-based registry study. Multiple Sclerosis Journal, 2015, 21, 147-154.	3.0	16

#	Article	IF	Citations
55	Risk Factors, Subtypes, and Outcome of Ischemic Stroke in Kuwait: A National Study. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2145-2152.	1.6	16
56	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal, 2020, 26, 1866-1876.	3.0	16
57	MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103225.	2.0	16
58	A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurology, 2016, 16, 240.	1.8	14
59	Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait. Multiple Sclerosis Journal, 2016, 22, 1086-1093.	3.0	14
60	Sensitivity of visual evoked potentials and spectral domain optical coherence tomography in early relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 12, 15-19.	2.0	14
61	Demographics and Clinical Characteristics of Multiple Sclerosis in Kuwait. European Neurology, 2014, 72, 181-185.	1.4	13
62	Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait. Journal of Neuroimmunology, 2015, 285, 57-61.	2.3	13
63	The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients. Scientific Reports, 2019, 9, 19071.	3.3	13
64	Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis. Pediatric Neurology, 2015, 53, 508-512.	2.1	12
65	Burden of migraine in a Kuwaiti population: a door-to-door survey. Journal of Headache and Pain, 2017, 18, 105.	6.0	12
66	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
67	Status migrainosus as an initial presentation of multiple sclerosis. SpringerPlus, 2015, 4, 28.	1.2	11
68	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
69	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	3.0	10
70	ZFAT gene variant association with multiple sclerosis in the Arabian Gulf population: A genetic basis for gender-associated susceptibility. Molecular Medicine Reports, 2016, 14, 3543-3550.	2.4	9
71	Assessment of plasma biomarkers for their association with Multiple Sclerosis progression. Journal of Neuroimmunology, 2017, 305, 5-8.	2.3	9
72	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.6	9

#	Article	IF	Citations
73	Joinpoint Regression Analysis of Trends in Multiple Sclerosis Incidence in Kuwait: 1980â€“2019. Neuroepidemiology, 2020, 54, 472-481.	2.3	9
74	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
75	Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait. Multiple Sclerosis and Related Disorders, 2019, 36, 101409.	2.0	8
76	Impact of Puberty in Girls on Prevalence of Primary Headache Disorder Among Female Schoolchildren in Kuwait. Frontiers in Neurology, 2020, 11, 594.	2.4	8
77	A matched case-control study of risk factors associated with multiple sclerosis in Kuwait. BMC Neurology, 2020, 20, 64.	1.8	8
78	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
79	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
80	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	2.2	8
81	Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry. Multiple Sclerosis and Related Disorders, 2020, 38, 101448.	2.0	7
82	Replication analysis of variants associated with multiple sclerosis risk. Scientific Reports, 2020, 10, 7327.	3.3	7
83	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
84	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. CNS Drugs, 2021, 35, 1097-1106.	5.9	7
85	Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clinical Neurology and Neurosurgery, 2020, 197, 106203.	1.4	6
86	Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgraduate Medicine, 2020, 132, 368-376.	2.0	6
87	The MSBase pregnancy, neonatal outcomes, and womenâ€™s health registry. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110091.	3.5	6
88	Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19. Neurology and Therapy, 2021, , 1-17.	3.2	6
89	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	3.0	6
90	Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?. International Journal of Neuroscience, 2017, 127, 944-951.	1.6	5

#	Article	IF	Citations
91	Risk factors of white matter hyperintensities in migraine patients. BMC Neurology, 2022, 22, 159.	1.8	5
92	Economic burden of multiple sclerosis on Kuwait health care system. PLoS ONE, 2019, 14, e0216646.	2.5	4
93	Angiopoietin-like proteins in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 31-34.	2.3	4
94	Primary Headache Disorder Among School Students in Kuwait. Frontiers in Neurology, 2021, 12, 621017.	2.4	4
95	Age-Period-Cohort Modeling of Multiple Sclerosis Incidence Rates in Kuwait: 1980â€“2014. Neuroepidemiology, 2017, 49, 152-159.	2.3	3
96	A longitudinal study of JC virus serostatus stability among multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2018, 20, 132-135.	2.0	3
97	The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642095411.	3.5	3
98	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
99	Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East. Journal of Clinical Neuroscience, 2022, 99, 311-316.	1.5	3
100	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
101	Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. Clinical Neurology and Neurosurgery, 2020, 196, 106047.	1.4	2
102	Family planning is the second most relevant factor for treatment decisions after disease activity â€“ Yes. Multiple Sclerosis Journal, 2020, 26, 640-641.	3.0	2
103	A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon Î²-1a. Multiple Sclerosis International, 2021, 2021, 1-7.	0.8	2
104	Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Clinical Neurology and Neurosurgery, 2021, 203, 106576.	1.4	2
105	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	3.2	2
106	Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait. International Journal of MS Care, 2012, 14, 17-24.	1.0	2
107	Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210771.	1.0	2
108	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2

#	Article	IF	Citations
109	Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine Patients. Frontiers in Neurology, 2020, 11, 633355.	2.4	1
110	Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731985019.	1.0	1
111	Recombinant hepatitis B vaccine uptake and multiple sclerosis risk: A marginal structural modeling approach. Multiple Sclerosis and Related Disorders, 2022, 58, 103487.	2.0	1
112	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
113	Yet another atypical presentation of anti-GQ1b antibody syndrome. Neurology International, 2015, 7, 5770.	2.8	0
114	A cortical stroke secondary to an isolated left ventricular noncompaction in a 29-year-old female. Indian Heart Journal, 2016, 68, S158-S160.	0.5	0
115	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
116	054â€…Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A22.2-A22.	1.9	0
117	Expert opinion on clinical experience with subcutaneous interferon betaâ€1a in multiple sclerosis patients with different disease activity profiles. Neurology and Clinical Neuroscience, 2019, 7, 260-266.	0.4	0
118	004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
119	Evaluation of disparities in multiple sclerosis risk by age, sex, and nativity in Kuwait:1980â€“2019. Multiple Sclerosis and Related Disorders, 2021, 47, 102676.	2.0	0
120	036â€… Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A24.3-A25.	1.9	0